Latest News & Updates
Not all HER2 genes are capable of causing cancer growth or spread, and thus may also fail to predict response to anticancer drugs that target the gene.
Mohammad Jahanzeb, MD, discusses emerging strategies in the adjuvant treatment of patients with HER2-positive breast cancer.
The FDA has approved necitumumab in combination with gemcitabine and cisplatin for the first-line treatment of patients with locally advanced or metastatic squamous non–small cell lung cancer.
William G. Wierda, MD, PhD, gives a better understanding of the changing landscape of chronic lymphocytic leukemia and how treatment options vary among different patient subtypes.
The primary analysis of the phase III CALGB 40601 trial found that pathologic complete response to dual HER2 blockade was not statistically higher than anti-HER2 monotherapy. However, there was a high level of intertumoral heterogeneity, and patients with the HER2-enriched subtype had a high pCR with both single and dual anti-HER2 therapy.
Latest Peer Exchange Discussions
James Natale, PharmD, BCOP, explains the various healthcare provider roles in the prevention and treatment of chemotherapy-induced nausea and vomiting. View Now
Morey Blinder, MD, describes advances made in iron chelation therapy, and his personal experience with the newest version, Jadenu. View Now
The panelists, Brian Van Tine, MD, PhD; Robin Jones, MD, MRCP; Shreyaskumar Patel, MD; Lor Randall, MD, FACS; Jonathan Trent, MD, PhD; and Andrew Wagner, MD, PhD, highlight some of the key members of their multidisciplinary teams who are sometimes overlooked. View Now
Most Popular Right Now
Online CME Activities